PHILADELPHIA--The Radiation Therapy Oncology Group (RTOG) has just
begun work on a potentially ground-breaking study of the use of
radioactive seed implants (brachytherapy) for cancer that is confined
to the prostate gland. The study will be the first
multi-institutional evaluation of the treatment. To date, a number of
single-institution studies have been conducted, showing the technique
to be effective in controlling the disease.
The new RTOG investigation will look closely at the potential side
effects of prostate brachytherapy as well as its effectiveness, said
Colleen Lawton, MD, study chair. Dr. Lawton is a radiation oncologist
at the Medical College of Wisconsin, Milwaukee.